Ono Kumeo, Tsuchida Akiyasu, Kawai Hironobu, Matsuo Hidenori, Wakamatsu Ryouji, Maezawa Akira, Yano Shintarou, Kawada Tomoyuki, Nojima Yoshihisa
Kan-etsu Chuo Hospital, Maebashi, Gunma, Japan.
J Am Soc Nephrol. 2003 Jun;14(6):1591-8. doi: 10.1097/01.asn.0000065547.98258.3d.
A reduction in ankle-brachial BP index (ABPI) is associated with generalized atherosclerotic diseases and predicts cardiovascular mortality and morbidity in several patient populations. However, a large-scale analysis of ABPI is lacking for hemodialysis (HD) patients, and its use in this population is not fully validated. A cohort of 1010 Japanese patients undergoing chronic hemodialysis was studied between November 1999 and May 2002. Mean age at entry was 60.6 +/- 12.5 yr, and duration of follow-up was 22.3 +/- 5.6 mo. Patients were stratified into five groups (< 0.9, > or = 0.9 to < 1.0, > or = 1.0 to < 1.1, > or = 1.1 to < 1.3, and > or = 1.3) by ABPI measured at entry by an oscillometric method. The frequency distribution of ABPI was 16.5% of patients < 0.9, 8.6% of patients > or = 0.9 to < 1.0, 16.9% of patients 1.0 > or = to < 1.1, and 47.0% of patients > or 1.1 to < 1.3, whereas 10.9% of patients had an abnormally high ABPI (> or = 1.3). The relative risk of a history of diabetes mellitus (DM), cardiovascular, and cerebrovascular disease was significantly higher in patients with lower ABPI than those with ABPI > or = 1.1 to <1.3. During the study period, 77 cardiovascular and 41 noncardiovascular fatal events occurred. On the basis of Cox proportional hazards regression analysis, ABPI emerged as a strong independent predictor of all-cause and cardiovascular mortality. After adjustment for confounding variables, the hazard ratio (HR) for ABPI < 0.9 was 4.04 (95% confidence interval, 2.38 to 6.95) for all-cause mortality and 5.90 (2.83 to 12.29) for cardiovascular mortality. Even those with modest reductions in the ABPI (> or = 0.9 to <1.1) appeared to be at increased risk. Patients having abnormally high ABPI (> or = 1.3) also had poor prognosis (HR, 2.33 [1.11 to 4.89] and 3.04 [1.14 to 8.12] for all-cause and cardiovascular mortality, respectively). Thus, the present findings validate ABPI as a powerful and independent predictor for all-cause and cardiovascular mortality among hemodialysis patients.
踝臂血压指数(ABPI)降低与全身性动脉粥样硬化疾病相关,并可预测多种患者群体的心血管死亡率和发病率。然而,目前缺乏对血液透析(HD)患者ABPI的大规模分析,其在该人群中的应用尚未得到充分验证。1999年11月至2002年5月期间,对1010例接受慢性血液透析的日本患者进行了一项队列研究。入组时的平均年龄为60.6±12.5岁,随访时间为22.3±5.6个月。通过示波法在入组时测量ABPI,将患者分为五组(<0.9、≥0.9至<1.0、≥1.0至<1.1、≥1.1至<1.3以及≥1.3)。ABPI的频率分布为:16.5%的患者<0.9,8.6%的患者≥0.9至<1.0,16.9%的患者≥1.0至<1.1,47.0%的患者≥1.1至<1.3,而10.9%的患者ABPI异常高(≥1.3)。ABPI较低的患者患糖尿病(DM)、心血管疾病和脑血管疾病的相对风险显著高于ABPI≥1.1至<1.3的患者。在研究期间,发生了77例心血管死亡事件和41例非心血管死亡事件。基于Cox比例风险回归分析,ABPI成为全因死亡率和心血管死亡率的有力独立预测指标。在对混杂变量进行调整后,ABPI<0.9的全因死亡率风险比(HR)为4.04(95%置信区间,2.38至6.95),心血管死亡率风险比为5.90(2.83至12.29)。即使是ABPI适度降低(≥0.9至<1.1)的患者,其风险似乎也有所增加。ABPI异常高(≥1.3)的患者预后也较差(全因死亡率和心血管死亡率的HR分别为2.33[1.11至4.89]和3.04[1.14至8.12])。因此,本研究结果验证了ABPI作为血液透析患者全因死亡率和心血管死亡率的有力独立预测指标。